Originally sourced from CMOCRO INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the […]
Irvine, CA —May 02, 2022 — ResearchDx will attend and exhibit at the ASCO Annual Meeting in Chicago, Il, June 3–7. Please visit our booth #22084, or call us at 760- 473-4295 to set up a consultation at the show.
Originally sourced from Business Wire NEW YORK–(BUSINESS WIRE)–Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that a new, wholly owned subsidiary of Lucid, LucidDx Labs Inc. (“LucidDx Labs”) has acquired from ResearchDx, Inc. (“RDx”), a CLIA-certified, CAP-accredited […]
ResearchDx will be exhibiting at AMP 2021 . Please visit us at booth #327. Additionally, our Chief Medical Officer Dr. Shelly Gunn will present the abstract: “Identification of a Novel Large F13A1 Intragenic Deletion by Targeted Next Generation Sequencing in a Patient with Factor X111 Deficiency.” Please call us at 760 473 4295 to set […]
Our CAP/CLIA certified lab, PacificDx is partnered with CHOC (Children’s Hospital of Orange County) to identify rare inherited blood disorders in infants and mothers to improve their quality of life. Written by Amanda Nguyen (March 2021) ____________________________________________________________________________________________________________________________________________________ The last royal family of Russia was speculated to be plagued with the “royal bleeding disease” passed down […]
PacificDX is the only lab certified to run trio-Smart™, a breath test developed by Gemelli™. Along with measuring the standard H2, CH4 and CO2 levels, trio-smart™ is the only BT that also measures hydrogen sulfide. You are at a fancy dinner party wearing your favorite dress. After the delicious meal, you are conversing with an […]
As Lucid Diagnostics’ commercial diagnostic laboratory partner, the new EsoGuard esophageal DNA laboratory-developed test (LDT) was developed and completed CLIA and CAP certification at ResearchDx’s premier molecular laboratory, PacificDx. The first of its kind, this non-invasive DNA test was designed to detect the presence of dysplastic and non-dysplastic Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC) […]
Brief: First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]
Irvine, CA — Jan 28, 2020 — ResearchDx will attend the Molecular Medicine Tri-Con Meeting in San Francisco California, March 1–4. Please visit our booth #600, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.
Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]